Skip to main content
Advertisement

< Back to Article

Table 1.

Parameters and notation of polygenic model.

More »

Table 1 Expand

Figure 1.

Expected −log10(P) of linear regression estimate as a function of P-value threshold for selecting markers into the polygenic score.

Training sample, 3322 cases and 3587 controls; replication sample, 2687 cases and 2656 controls. Marker panel of 74062 independent SNPs. Variance explained by markers, 28.7%. pi0, proportion of markers with no effect on disease.

More »

Figure 1 Expand

Figure 2.

Expected −log10(P) of allele score estimate as a function of P-value threshold for selecting markers into the polygenic score.

Training sample, 3322 cases and 3587 controls; replication sample, 2687 cases and 2656 controls. Marker panel of 74062 independent SNPs. Variance explained by markers, 28.7%. pi0, proportion of markers with no effect on disease.

More »

Figure 2 Expand

Table 2.

AUC calculated by Evans et al [19] compared to analytic values when () marker panel explains half the heritability, or () marker panel explains the full heritability.

More »

Table 2 Expand

Table 3.

R2 reported for complex diseases compared to analytic values when marker panel explains one quarter, one half or the full heritability.

More »

Table 3 Expand

Figure 3.

AUC as a function of sample size, using a panel of 100,000 markers that explains half the heritability of liability.

n, number of cases and of controls in training sample. Heritability of liability, 76% for Crohn's disease. 44% for breast cancer. Line annotations are the proportion of markers with no effect on disease.

More »

Figure 3 Expand

Table 4.

Numbers of cases and controls (in 1000s of each, rounded up) required to attain a specified AUC using a panel of 100,000 markers that explains half the heritability of liability.

More »

Table 4 Expand

Figure 4.

AUC as a function of sample size, using a panel of 1,000,000 markers that explains the full heritability.

n, number of cases and of controls in training sample. Heritability of liability, 76% for Crohn's disease. 44% for breast cancer. Line annotations are the proportion of markers with no effect on disease.

More »

Figure 4 Expand

Table 5.

Numbers of cases and controls (in 1000s of each, rounded up) required to attain a specified AUC using a panel of 1,000,000 markers that explains the full heritability.

More »

Table 5 Expand

Table 6.

Numbers of subjects (in 1000s, rounded up) required to attain a specified correlation with a normal trait using a panel of 1,000,000 markers that explains the full heritability.

More »

Table 6 Expand